Physician profile
Son T DO
NPI 1871552224
$106,164.19
in general payments reported to CMS, 2019-2025
51 companies · $9,334 in 2025
The $9,334 reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $6,642 · 2021: $15K · 2022: $17K · 2023: $8,609 · 2024: $15K · 2025: $9,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $10K · Consulting Fee: $1,200 · Travel and Lodging: $1,151 · Education: $54.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,860.00 |
| Food and Beverage | $10,354.71 |
| Consulting Fee | $1,200.00 |
| Travel and Lodging | $1,150.55 |
| Education | $54.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $88,380.04 | 2019-2025 | Vemlidy |
| Abbvie INC. | $4,484.44 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $2,126.30 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,733.69 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,300.89 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $1,200.00 | 2023 | |
| Qol Medical, LLC | $545.38 | 2019-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $519.27 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Regeneron Healthcare Solutions, INC. | $508.48 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $468.77 | 2024-2025 | Voquezna |
| Genzyme Corporation | $426.23 | 2022-2025 | |
| Redhill Biopharma INC. | $354.60 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Nestle Healthcare Nutrition INC. | $281.68 | 2021-2023 | |
| Pfizer INC. | $276.45 | 2019-2025 | |
| Celgene Corporation | $255.00 | 2021-2024 | Zeposia |
Show all 50 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$37,833.81 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Son DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.